CAN URINE BOUND DIAGNOSTIC TESTS REPLACE CYSTOSCOPY IN THE MANAGEMENT OF BLADDER CANCER?
- 1 June 1998
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 159 (6) , 1876-1880
- https://doi.org/10.1016/s0022-5347(01)63184-7
Abstract
We compare the diagnostic value of NMP22 and BTA stat testing, and QUANTICYT computer assisted dual parameter image analysis to cytology and cystoscopy in patients who had symptoms suggestive of transitional cell cancer or were being followed after treatment for that disease. We prospectively evaluated voided urine and/or barbotage specimens from 291 patients a mean of 65.2 years old. All voided urine samples were evaluated by quick staining and standard cytology, the BTA stat 1-step qualitative assay (which detects a bladder tumor associated antigen) and the NMP22 test (which detects a nuclear mitotic apparatus protein). In addition, barbotage specimens were evaluated by QUANTICYT computer assisted dual parameter image analysis. All patients underwent subsequent cystoscopy and biopsy evaluation of any suspicious lesion. Sensitivity, specificity, and the predictive value of positive and negative results were determined in correlation with endoscopic and histological findings. In 91 patients with histologically proved transitional cell carcinoma overall sensitivity was 48, 57, 58, 59 and 59% for the NMP22 test, the BTA stat test, rapid staining cytology of barbotage samples, rapid staining cytology of voided urine specimens and image analysis, respectively. For histological grades 1 to 3 underlying transitional cell carcinoma sensitivity was 17, 61 and 90% for urinary cytology, 48, 58 and 63% for the BTA stat test, and 52, 45 and 50% for the NMP22 test, respectively. Specificity was 100% for cytology, 93% for image analysis, 70% for the NMP22 test and 68% for the BTA stat test. Immunological markers are superior to cytological evaluation and image analysis for detecting low grade transitional cell carcinoma but they have low specificity and sensitivity in grade 3 transitional cell carcinoma. Urine bound diagnostic tools cannot replace cystoscopy.Keywords
This publication has 10 references indexed in Scilit:
- Clinical Evaluation of Nuclear Matrix Protein 22 (NMP22) in Urine as a Novel Marker for Urothelial CancerEuropean Urology, 1997
- Quanticyt: Karyometric analysis of bladder washing for patients with superficial bladder cancerUrology, 1996
- Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical TreatmentJournal of Urology, 1996
- Initial Evaluation of the Bladder Tumor Antigen Test in Superficial Bladder CancerJournal of Urology, 1996
- Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder CancerJournal of Urology, 1995
- Editorial CommentJournal of Urology, 1995
- Soluble forms of the adhesion molecule E-cadherin in urine.Journal of Clinical Pathology, 1995
- Biology and Management of Bladder CancerNew England Journal of Medicine, 1990
- Analysis of the performance of pathologists in the grading of bladder tumorsHuman Pathology, 1983